CD44 Disruption Attenuates Murine Hepatic Ischemia/Reperfusion Injury

• Published in: Journal of Korean medical science Vol. 26; no. 7; pp. 919 - 926
• Main Authors: Kim, Min Sung, Lee, Ki Ho, Lee, Won Mee, Jun, Jin Hyun, Kim, Dong Hee
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 01.07.2011; 대한의학회
• Subjects: Alanine Transaminase - blood; Animals; Antibodies - immunology; Antibodies - pharmacology; Cytokines - metabolism; Disease Models, Animal; Hyaluronan Receptors - immunology; Hyaluronan Receptors - metabolism; Hyaluronan Receptors - physiology; Liver - metabolism; Liver - pathology; Male; Mice; Mice, Inbred C57BL; Neutrophils - immunology; Neutrophils - physiology; Original; Reperfusion Injury - metabolism; Reperfusion Injury - pathology; Reperfusion Injury - prevention & control; 의학일반; Inflammation; Ischemia/Reperfusion; Liver; CD44; Neutrophils; Recruitment
• ISSN: 1011-8934; 1598-6357; 1598-6357
• DOI: 10.3346/jkms.2011.26.7.919

Neutrophil adhesion and migration are critical in hepatic ischemia/reperfusion (I/R) injury. Despite very strong preclinical data, recent clinical trials failed to show a protective effect of anti-adhesion therapy in reperfusion injury. Therefore, the aim of this study was to assess the role of CD44 in neutrophil infiltration and liver injury from hepatic I/R. In this study, using a partial hepatic ischemic model in vivo, we determined the potential role of CD44 in neutrophil infiltration and liver injury from I/R. Reperfusion caused significant hepatocellular injury as it was determined by plasma ALT levels and liver histopathology. The injury was associated with a marked neutrophil recruitment and CD44 expression into the ischemic livers. Administration of anti-CD44 antibody to mice reduced the infiltration of neutrophil into the ischemic tissue, associated with liver function preservation. These results support crucial roles of CD44 in neutrophil recruitment and infiltration leading to liver damage in hepatic I/R injury. Moreover, they provide the rationale for targeting to CD44 as a potential therapeutic approach in liver I/R injury.